Future Market Insights (FMI) has unveiled a compelling new report forecasting significant expansion in the global fuchs endothelial corneal dystrophy market. The report highlights a surge in market value from USD 180 billion in 2023 to an anticipated USD 370 billion by 2033, marking a robust Compound Annual Growth Rate (CAGR) of 7.5% over the forecast period.
Several pivotal factors are driving this impressive market growth. The increasing prevalence of Fuchs’ endothelial corneal dystrophy is generating a higher demand for advanced treatment options. As the global population ages, the incidence of age-related diseases like FECD is rising, further accelerating the need for effective healthcare solutions.
The demographic shift towards an aging population is a significant contributor to the market’s expansion. With the number of elderly individuals increasing, the demand for treatments addressing age-related eye conditions is expected to climb. Additionally, heightened awareness efforts by governmental and private organizations about eye disorders and the promotion of corneal donation are set to bolster market growth.
The surge in research focusing on cellular treatment techniques is also expected to create lucrative opportunities within the FECD market. The growing emphasis on comprehensive eye care services is further fueling the demand for innovative solutions.
FMI’s report provides an in-depth analysis of the market dynamics, competitive landscape, and key trends shaping the future of the global FECD market. It offers actionable insights for industry stakeholders, equipping them with the intelligence needed to make informed decisions and seize emerging opportunities.
Key Takeaways from the Market Study:
- FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
- The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of USD 180 Billion
- The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of USD 370 Billion
- As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023-2033.
- North America is expected is expected to grow at a CAGR of 7.4% in the assessment period 2023-2033.
- Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023-2033.
- The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market in the forecast period 2023-2033.
“Asia-Pacific is predicted to rise over the projected period of 2023-2033 due to increased R&D activities, increased investment in the healthcare industry, and more government assistance,” says an analyst at FMI
Explore the High Demand for Fuchs Endothelial Corneal Dystrophy: Our Full Report Provides a Detailed Look at Emerging Trends!
Market Competition:
Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are
- Kowa Pharmaceuticals
- Trefoil Therapeutics
- Alcon
- Emmecell
- Santen
- AJL Ophthalmic SA
- Massachusetts Eye and Ear
- KeraMed, Inc.
- Presbia Plc
In May 2022, SEGLENTIS® C-IV is now available for purchase through Kowa Pharmaceuticals America, Inc.
Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey:
By Treatment:
- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
By Diagnosis:
- Slit-lamp Examination
- Molecular Genetic Tests
- Pachymetry
By End User:
- Hospitals
- ASCs
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube